GRAIL Inc. (GRAL)
GRAL Stock Price Chart
Explore GRAIL Inc. interactive price chart. Choose custom timeframes to analyze GRAL price movements and trends.
GRAL Company Profile
Discover essential business fundamentals and corporate details for GRAIL Inc. (GRAL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Jun 2024
Employees
910.00
Website
http://www.grail.comCEO
Robert Ragusa
Description
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
GRAL Financial Timeline
Browse a chronological timeline of GRAIL Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$2.66, while revenue estimate is $42.39m.
Earnings released on 5 May 2026
EPS came in at -$2.29 surpassing the estimated -$2.76 by +17.11%, while revenue for the quarter reached $40.79m , beating expectations by +4.16%.
Earnings released on 19 Feb 2026
EPS came in at -$2.44 surpassing the estimated -$3.33 by +26.73%, while revenue for the quarter reached $43.60m , beating expectations by +0.04%.
Earnings released on 12 Nov 2025
EPS came in at -$2.46 surpassing the estimated -$3.36 by +26.79%, while revenue for the quarter reached $36.19m , beating expectations by +4.61%.
Earnings released on 12 Aug 2025
EPS came in at -$3.18 falling short of the estimated -$3.14 by -1.27%, while revenue for the quarter reached $35.54m , beating expectations by +4.23%.
Earnings released on 13 May 2025
EPS came in at -$3.10 surpassing the estimated -$4.03 by +23.08%, while revenue for the quarter reached $31.84m , missing expectations by -9.55%.
Earnings released on 20 Feb 2025
EPS came in at -$1.86 surpassing the estimated -$4.41 by +57.82%, while revenue for the quarter reached $38.25m , beating expectations by +6.85%.
Earnings released on 12 Nov 2024
EPS came in at -$3.94 surpassing the estimated -$6.43 by +38.72%, while revenue for the quarter reached $28.65m , missing expectations by -16.71%.
Earnings released on 13 Aug 2024
EPS came in at -$5.30 , while revenue for the quarter reached $31.97m .
Earnings released on 31 Mar 2024
EPS came in at -$7.05 , while revenue for the quarter reached $26.72m .
Earnings released on 31 Dec 2023
EPS came in at -$0.18 , while revenue for the quarter reached $30.33m .
Earnings released on 30 Sept 2023
EPS came in at -$28.71 , while revenue for the quarter reached $20.72m .
Earnings released on 29 Jun 2023
EPS came in at -$6.22 , while revenue for the quarter reached $22.41m .
Earnings released on 2 Apr 2023
EPS came in at -$6.24 , while revenue for the quarter reached $19.64m .
GRAL Stock Performance
Access detailed GRAL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
